President of Lupin Somerset
| Pharmaceutics International, Inc
I am currently, VP of US Development, Portfolio and Launch Management at Sandoz. Sandoz, part of the Novartis group (NYSE:NVS), is one of the largest manufacturers of generic pharmaceutical products in the United States and markets approximately 200 different generic medicines in the US, including enoxaparin sodium injection, the first generic version of Lovenox®, and Omnitrope®, the first follow-on biologic available in the US. in business. Previous leadership roles were Senior Vice President of R&D and Chief Technology Officer for Catalent Inc. (NYSE:CTLT), Executive Vice President of Pharmaceuticals for URL Pharma and Executive Director of Generic R&D for TEVA Pharmaceuticals (NYSE:TEVA). My 20+ years of experience in generic, brand, biotech and consumer health pharmaceutical companies includes a strong background in managing businesses, developing and launching new products for global markets, regulatory strategy, sales and marketing of products and technologies, complex international licensing transactions, as well as, M&A. Lastly, my organizational leadership responsibilities in B2C and B2B companies includes a variety of entrepreneurial and corporate environments (e.g. matrixed global organizations with multiple business units), as well as, recruiting, building and retaining talented teams of leaders and managers.